IMMU-22. EARLY RELEASE OF TYPE I INTERFERON DRIVES BRAIN CANCER IMMUNOGENICITY AND RESPONSE TO IMMUNOTHERAPY

BACKGROUND: Molecular drivers of cancer immunogenicity in brain tumors are still being unraveled. While BATF3 expression, STING, and interferon response factors (IRFs) are necessary for cancer immunogenicity, the presence of type I interferon (IFN-I) is contextual having been reported to elicit both...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Wummer, Brandon, Qdaisat, Sadeem, Grippin, Adam, Karachi, Aida, Weidert, Frances, Huang, Jianping, Rahman, Maryam, Mitchell, Duane, Mendez-Gomez, Hector, Sayour, Elias
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2020
Materias:
Immunology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651403/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.452
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares